John Hopkins New Mebendazole Patient

https://www.facebook.com/share/p/1CU1QfHe5u/

Johns Hopkins’ New Mebendazole Patent and Its Significance for Cancer Therapeutics

A recent public news article has highlighted a development that deserves serious attention within oncology and drug-repurposing research:

Johns Hopkins scientists have patented a new crystalline form of mebendazole—referred to as polymorph C—designed to enhance its anti-cancer properties.

Background: Why Mebendazole Matters

Mebendazole is a benzimidazole-class anthelmintic with a well-characterised safety profile accumulated over ~40 years of clinical use. Beyond its antiparasitic activity, numerous preclinical studies have demonstrated:

Microtubule inhibition in cancer cells

Disruption of glucose metabolism in malignant tissues

Interference with multiple signalling pathways (Hh, Wnt/β-catenin, Bcl-2)

Selective cytotoxicity to tumour cells at concentrations tolerated by normal cells

Despite these properties, clinical adoption has been limited largely because the original molecule is off-patent, making large-scale commercial trials financially unviable.

What Johns Hopkins Has Patented

The new patent centers on:

Polymorph C — a redesigned crystalline form

This form appears to demonstrate:

Improved oral absorption

Higher plasma concentrations

Prolonged systemic exposure

Greater potency in killing cancer cells in vitro compared with existing polymorphs

This is scientifically notable, because mebendazole traditionally suffers from:

Poor gastrointestinal absorption

High inter-individual variability

Low bioavailability unless taken with high-fat meals

A more bioavailable crystalline form directly addresses these limitations.

Synergy Through Transporter Inhibition

The Johns Hopkins team also referenced co-administration with elacridar, a potent inhibitor of:

P-glycoprotein (P-gp)

Breast Cancer Resistance Protein (BCRP)

These efflux pumps are responsible for removing chemotherapeutic agents from cancer cells.

Inhibiting them has the potential to:

Increase intracellular retention of mebendazole

Enhance apoptosis

Overcome multi-drug resistance mechanisms

This combination strategy reflects a rational, mechanistic approach to amplifying the drug’s cytotoxic effects.

Why This Patent Is Scientifically Significant

It provides a patentable molecular form, which opens a viable commercial pathway for clinical development.

It acknowledges, from a top-tier research institution, the credible mechanistic basis behind mebendazole’s anti-cancer activity.

It strengthens the case for repurposing older, well-characterised medicines — a field historically underfunded due to absent commercial incentives.

It may accelerate formal clinical trials that were previously blocked by economic constraints rather than scientific merit.

Broader Impact

This development represents more than a single drug patent. It reflects a larger shift.

A move toward molecular refinement of existing compounds

Recognition of repurposing as a legitimate domain of oncologic innovation

The possibility of bringing safe, inexpensive, low-toxicity medicines into mainstream oncology—provided they can be placed within a patentable and fundable framework

Importantly, today’s public coverage brings visibility to a topic long confined to laboratory research, academic papers, and integrative oncology communities.

The Johns Hopkins polymorph C patent is not simply a new formulation—it is an important scientific and economic bridge enabling a well-known, extremely safe molecule to finally progress into the rigorous clinical environments it has scientifically deserved for years.

If further research confirms the early findings, this could mark a meaningful step forward in targeted drug repurposing for oncology.

#DrugRepurposing #OncologyResearch #Mebendazole #PolymorphC #JohnsHopkins #TranslationalMedicine #CancerTherapeutics #EffluxInhibition #Pgp #BCRP #IntegrativeOncology #PreclinicalEvidence #Bioavailability #AnticancerResearch

6 comments